Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate 14.02.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The data will also be presented tomorrow as part of three abstracts at the currently ongoing International Society on Thrombosis and Haemostasis (ISTH) 2025 Congress The Phase III AdFIrst study met ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Successful interim analysis performed with 80% of evaluable patients Originally planned number of patients confirmed Completion of trial expected in 2023 AdFIrst trial will be the basis for approval ...

Grifols, one of the world’s leading producers of plasma-derived medicines, announced that Biotest’s positive topline results from AdFIrst, its phase 3 clinical trial of its fibrinogen concentrate (FC) ...

Dreieich, 23 June 2025. Biotest today announces that the positive Phase III study data on its fibrinogen concentrate, BT524, has been published in eClinicalMedicine, a peer-reviewed journal published ...

Positive results confirm excellent safety profile Top-line data demonstrate that Fibrinogen concentrate treatment is as effective as standard of care, either cryoprecipitate or fresh frozen plasma, in ...

BARCELONA, Spain, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world’s leading producers of plasma-derived medicines, today announced that Biotest’s ...

In the AdFIrst study, Biotest's fibrinogen concentrate (FC), BT524, met the primary endpoint, demonstrating its effectiveness in treating acquired fibrinogen deficiency (AFD) as equivalent to standard ...